CORTICOSTEROID THERAPY ASSOCIATED WITH COVID-19: AN ALLY OR A RISK FACTOR FOR THE ESTABLISHMENT OF SECONDARY FUNGAL CO-INFECTIONS?

An allied or a risk factor for the secundary fungal co-infections establishment?

Autores

  • Thaís Ferreira do Amaral Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul. Porto Alegre, RS, Brasil. https://orcid.org/0000-0002-6821-932X
  • Natália Monteiro da Silva Rodrigues Coutinho Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul. Porto Alegre, RS, Brasil. https://orcid.org/0000-0002-6788-7238
  • Rubia do Nascimento Fuentefria Hospital de Clínicas de Porto Alegre. Porto Alegre, RS, Brasil.
  • Alexandre Meneghello Fuentefria Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul. Porto Alegre, RS, Brasil. https://orcid.org/0000-0003-2979-4417
  • Gabriella da Rosa Monte Machado Machado Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul. Porto Alegre, RS, Brasil.

DOI:

https://doi.org/10.22491/2357-9730.124623

Resumo

Introduction: the corticosteroids therapy to combat inflammation caused by SARS-CoV-2 appears to be a risk factor for the secondary fungal co-infections development.

Methods: pubmed and science direct databases, using the following words group: [(aspergillosis OR mucormycosis OR candidiasis) AND (coronavirus disease) AND (corticoids) were used for this review. The selected articles present the main risk factors related to the secondary fungal co-infections establishment in COVID-19 patients.

Results: the corticosteroid therapy use to combat inflammation caused by SARS-CoV-2 has been shown to be strongly associated with mucormycosis and aspergillosis establishment. Mucormycosis has been the main fungal co-infection related to corticosteroid therapy, causing a greater number of deaths in COVID-19 patients. Diabetes mellitus was the most prevalent comorbidity, mainly for the mucormycosis establishment. The dexamethasone use seems to be associated with the mucormycosis emergence and to death. However, aspergillosis showed a greater relationship with patient recovery. Thus, risk factors such as diabetes mellitus, combined with corticosteroids use, have shown a relationship to the mucormycosis establishment.

Conclusion: the corticosteroids use in COVID-19 patients should be individually analyzed, taking into account mainly the patient's medical history and the risk/benefit ratio of the use of these drugs.

Downloads

Não há dados estatísticos.

Downloads

Publicado

03-03-2023

Como Citar

1.
Ferreira do Amaral T, Monteiro da Silva Rodrigues Coutinho N, do Nascimento Fuentefria R, Meneghello Fuentefria A, Machado G da RMM. CORTICOSTEROID THERAPY ASSOCIATED WITH COVID-19: AN ALLY OR A RISK FACTOR FOR THE ESTABLISHMENT OF SECONDARY FUNGAL CO-INFECTIONS? An allied or a risk factor for the secundary fungal co-infections establishment?. Clin Biomed Res [Internet]. 3º de março de 2023 [citado 11º de agosto de 2025];42(4). Disponível em: https://seer.ufrgs.br/index.php/hcpa/article/view/124623

Edição

Seção

Artigos de Revisão

Artigos mais lidos pelo mesmo(s) autor(es)